Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02830542 · ClinicalTrials.gov registry record · Phase 1
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
A Phase 1 study, sponsored by Seres Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT02830542 is a Phase 1 study that has completed, run by Seres Therapeutics. The registered enrollment target is 96 participants.
The verdict
NCT02830542, a Phase 1 study, has completed, sponsored by Seres Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
The study will involve administering a single dose of investigational drug or placebo in ascending dose cohorts. This study is designed to evaluate the safety and tolerability of investigational drug as well as the efficacy of investigational drug versus placebo in adults with primary (first episode) Clostridium difficile infection (CDI).
Interventions
- DRUG Placebo
- DRUG SER-262
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2016-08 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02830542
The ClinicalTrials.gov registry entry for NCT02830542 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seres Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02830542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02830542 about?
NCT02830542 is a clinical study titled "SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence". The study will involve administering a single dose of investigational drug or placebo in ascending dose cohorts. This study is designed to evaluate the safety and tolerability of investigational drug as well as the efficacy of investigational drug versus placebo in adults with primary (first episode...
What is the current status of trial NCT02830542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2016-08. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02830542?
The interventions under investigation include: Placebo (DRUG), SER-262 (DRUG).
Who is sponsoring clinical trial NCT02830542?
This trial is sponsored by Seres Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.